Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Omixon logo — Our mission: enabling histocompatibility labs to turn the be...

Omixon

Our mission: enabling histocompatibility labs to turn the benefits of innovative techs into better transplant outcomes

Founded 2011 Hungary Hungary 58 employees Series C Biotechnology

General Information

Company Name Omixon
Founded Year 2011
Location Hungary Hungary +2
Employees 58
Industries Biotechnology
Funding Stage Series C
Social

Get notified when Omixon moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Omixon

Omixon, founded in 2011 and headquartered in Hungary, is a prominent player in the biotechnology industry. The company's mission, as outlined in their slogan, is to enable histocompatibility labs to harness the benefits of innovative technologies for improved transplant outcomes. Omixon's global presence spans across the United States, Brazil, and the Netherlands, extending its reach to more than 100 laboratories worldwide. Known for its multidisciplinary expertise in bioinformatics, software engineering, molecular biology, and regulatory science, Omixon has been instrumental in translating molecular biology innovations into cutting-edge products for transplant diagnostics. The company achieved a significant milestone in 2014 by becoming the first to successfully introduce NGS-based HLA typing kit and software with the launch of Holotype HLA and HLA Twin. These products are revered for delivering highly accurate high-resolution HLA genotyping and are extensively utilized in 100+ laboratories worldwide. Omixon continued its trailblazing efforts with the release of the NanoTYPE HLA™, a high-resolution HLA genotyping product offering a remarkable turnaround time of less than 5 hours on the Oxford Nanopore sequencing platform, complemented by the NanoTYPER™ analysis software. Furthermore, the company made waves in the industry with the introduction of the groundbreaking HoloGRAFT, the first donor-derived cell-free DNA kit designed for laboratories and featuring donor-informative genetic markers. Primed for strategic growth, Omixon attracted a Series C investment on 05 January 2017, led by Marton Szoke and FastVentures. Stepping into a new chapter, Omixon's acquisition by Werfen was finalized in Barcelona, Spain, on October 16, 2024, following the attainment of all requisite regulatory and antitrust approvals. This acquisition marks a pivotal moment in Omixon's trajectory, positioning the company for potential advancements and expanded opportunities within the biotechnology landscape.

Taxonomy: Transplant diagnostics, HLA genotyping, Molecular biology, Bioinformatics, NGS-based technology, Regulatory science, Histocompatibility laboratories, Innovative technologies, Global operations, Software engineering, High-resolution genotyping, Oxford Nanopore sequencing, Cell-free DNA analysis, Donor-informative genetic markers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 2 •••• •••• 05 Jan 2017
Series B •••••• 2 •••• •••• 01 Feb 2015
Series A •••••• 2 •••• •••• 30 May 2012
Series A •••••• 1
Investor
12 Mar 2012

Omixon Alternatives & Competitors

Omixon vs
PIRCHE
PIRCHE Germany

Everyone who needs a transplant deserves an optimal match.

20 employees
Omixon vs
Eisai Pharmaceuticals India
Eisai Pharmaceuticals India India

Human Health Care Is Our Mission

606 employees
Manufacturing, Pharmaceutical
Compare Omixon vs Eisai Pharmaceuticals India

FAQ About Omixon

Our mission: enabling histocompatibility labs to turn the benefits of innovative techs into better transplant outcomes
Omixon was founded in 2011.
Omixon is headquartered in Hungary.
Omixon operates in the following industries: Biotechnology.
Omixon has approximately 58 employees.
Omixon has completed 4 funding rounds. The latest funding stage is Series C.
Top alternatives and competitors to Omixon include PIRCHE, Eisai Pharmaceuticals India. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Omixon and PIRCHE are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Omixon and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy